A simple to use, accurate and cost-effective blood test for large-scale colon cancer screening

Descripción del proyecto

Un innovador análisis de sangre para la detección del cáncer colorrectal

La empresa española biomédica Universal Diagnostics (UDX) se centra en la detección temprana del cáncer. Para ello, está trabajando en un método eficiente y de bajo coste para la detección de marcadores metabólicos tempranos en la sangre para diferentes tipos de cáncer mediante análisis basados en la espectrometría de masas. Si se diagnostica pronto, el cáncer colorrectal es una enfermedad tratable. UDX ha desarrollado una prueba de cribaje basada en la sangre que es precisa, no invasiva y económica; sirve para detectar el cáncer colorrectal y adenomas precancerosos, lo que facilita su prevención y tratamiento temprano. La plataforma de metabolómica desarrollada para el cáncer colorrectal puede modificarse fácilmente y aplicarse a la detección de otros tipos de cáncer. El equipo del proyecto ColonScan, financiado con fondos europeos, tiene previsto llevar a cabo estudios de viabilidad técnica y financiera para la comercialización del método de cribaje del cáncer colorrectal.

Objetivo

Universal Diagnostics (UDX) is a biomedicine start-up focused on early detection of cancer using leading-edge technologies. Our mission is to make cancer a curable disease by detecting it early through an accurate, simple to use, and cost-effective diagnostic kit.
During the last 5 years, UDX has been developing a mass spectrometry (MS) based metabolic analysis that allows very cost-effective and accurate detection of metabolic markers in blood, for early detection of different types of cancer.
The first product of the company (the one this proposal is all about) is ColonScan: A simple, noninvasive, accurate (AUC 92%) and inexpensive, blood-based screening test to detect colorectal cancer (CRC) and adenomas (precancerous stages), allowing early detection and cancer prevention.
ColonScan will be highly accurate, easily scalable worldwide, simple to use, non-invasive and inexpensive; ColonScan presents all characteristics and requirements to be adopted as CRC screening program for average risk population since, our technology can be included routinely in normal blood tests at annual or biannual medical check-ups. Moreover, the metabolomics platform developed in ColonScan project can be applied and upscaled to other types of cancer with no cost increase.
CRC is the third most commonly diagnosed and leading cause of cancer death in the world, despite CRC is considered a completely preventable disease. All CRC guidelines recommends regularly (annual or biannual) screening of average risk population (50-85 years old).
This represents a huge market opportunity, which according to our conservative estimations means a target population of 380 Million people and 12 Billion market opportunity.
The ultimate objective of ColonScan Phase 1 project is to assess the feasibility of our business innovation project, under a commercial, technical and financial point of view to minimize any potential risk that might endanger our business plan.

Ámbito científico

Programa(s)

Tema(s)

EIC-SMEInst-2018-2020 - SME instrument

Convocatoria de propuestas

H2020-EIC-SMEInst-2018-2020

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-SMEInst-2018-2020-1

Régimen de financiación

SME-1 - SME instrument phase 1

Coordinador

UNIVERSAL DIAGNOSTICS SOCIEDAD ANONIMA

Aportación neta de la UEn

€ 50 000,00

Dirección

AVENIDA REINA MERCEDES S/N EDIFICIO CELESTINO MUTI II)
41012 SEVILLA
España

Pyme

Sí

Región

Sur Andalucía Sevilla

Tipo de actividad

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Enlaces

Contactar con la organización

Participación en los programas de I+D de la UE

Red de colaboración de HORIZON

Coste total

€ 71 429,00